# Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma

> **NCT00583674** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 171 (actual)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **DRUG:** AMG 386 placebo
- **DRUG:** AMG 386 10mg/kg
- **DRUG:** AMG 386 3mg/kg
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00583674
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-03
- **Final completion:** 2012-06
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2014-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00583674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00583674, "Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00583674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*